Gemcitabine

For research use only.

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

106 publications

Gemcitabine  Chemical Structure

CAS No. 95058-81-4

Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) RMB 1057.63 In stock
RMB 782.86 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Gemcitabine has been cited by 106 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NVSxPHVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DBNGlEPTB;MD6wNFA1PThibl2= Mli1V2FPT0WU
ES4 NH[yclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMECwOlU{KG6P NUXoeZBYW0GQR1XS
ACHN NIXnRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LtVmlEPTB;MD6wNFA5QDdibl2= NWT0fpp1W0GQR1XS
KYSE-510 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP1TWM2OD1yLkCwNFk4PSCwTR?= NIL0PY1USU6JRWK=
EW-7 NH\6d|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPDT3BKSzVyPUCuNFAzPThibl2= NFLQZpBUSU6JRWK=
BFTC-905 NXju[JI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMEC1NVUhdk1? NIXLZYJUSU6JRWK=
KE-37 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS0U|Z{UUN3ME2wMlAxPTZzIH7N M3zPZnNCVkeHUh?=
SBC-5 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPuTWM2OD1yLkCwOVchdk1? M4[4TXNCVkeHUh?=
NKM-1 MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILGOWlKSzVyPUCuNFA4ODlibl2= MVnTRW5ITVJ?
RH-1 NIGxPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEC3NVghdk1? M4\u[3NCVkeHUh?=
ALL-PO MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTpNmFrUUN3ME2wMlAxQDNibl2= NFzZVHpUSU6JRWK=
QIMR-WIL NInibIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7ZOIJKSzVyPUCuNFA5QTRibl2= NHzkTG1USU6JRWK=
A375 NVnYcHFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEC5PVUhdk1? NGnOZWlUSU6JRWK=
SIG-M5 NH7OTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMEGwOEBvVQ>? M3PDRnNCVkeHUh?=
KGN MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;ReVBuUUN3ME2wMlAyODhibl2= MmT0V2FPT0WU
EW-13 NIPsbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G1[2lEPTB;MD6wNVEzKG6P MV;TRW5ITVJ?
NCI-SNU-1 NHHZepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjUTWM2OD1yLkCxOkBvVQ>? MnrRV2FPT0WU
PSN1 M3SwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;EeJJKSzVyPUCuNFE3PSCwTR?= NGfKRnZUSU6JRWK=
HUTU-80 NGjoZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMEG2OkBvVQ>? MVrTRW5ITVJ?
EW-16 M2j4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrwS|FiUUN3ME2wMlAzOyCwTR?= MnPNV2FPT0WU
786-0 MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMEKzJI5O M2fUfnNCVkeHUh?=
ES1 M4TxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXWPI9EUUN3ME2wMlAzPjhibl2= Mn3wV2FPT0WU
RKO MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwMEK3PUBvVQ>? MXPTRW5ITVJ?
ESS-1 M4HhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjmPVdKSzVyPUCuNFI5PiCwTR?= M4PlTnNCVkeHUh?=
SK-UT-1 NXjLfWhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXlTWM2OD1yLkCyPVchdk1? MkTyV2FPT0WU
LB2241-RCC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEOxPEBvVQ>? MVfTRW5ITVJ?
CHL-1 NU\0Rpo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T1SGlEPTB;MD6wN|I1KG6P M3HYbXNCVkeHUh?=
SW1783 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3R[FkzUUN3ME2wMlA{OzZibl2= M3jDUHNCVkeHUh?=
MEL-JUSO MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMEO5NUBvVQ>? M4rmZXNCVkeHUh?=
HT-29 NVHST29WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnoTWM2OD1yLkC0NVMhdk1? NGnRNXhUSU6JRWK=
SNG-M NVvPPIV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm1SYZWUUN3ME2wMlA1OjVibl2= NVnKWJZjW0GQR1XS
TE-15 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;HR3VKSzVyPUCuNFQ3PCCwTR?= M2XkR3NCVkeHUh?=
HOS NILCUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\3WmlEPTB;MD6wOFghdk1? MXTTRW5ITVJ?
BB65-RCC NV\JVlU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjVVoZKSzVyPUCuNFUyOiCwTR?= M2rhfHNCVkeHUh?=
HCE-4 MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHNN4dKSzVyPUCuNFUzQCCwTR?= NHn1cnJUSU6JRWK=
MHH-ES-1 NIPlVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfDVmpFUUN3ME2wMlA2OzFibl2= MkPvV2FPT0WU
RPMI-7951 MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\yOGlEPTB;MD6wOVQyKG6P MWPTRW5ITVJ?
IST-SL2 NHXuUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PpWmlEPTB;MD6wOVg1KG6P MkjVV2FPT0WU
CMK Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XxdWlEPTB;MD6wOVg3KG6P NF;SeG5USU6JRWK=
GR-ST NInTOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMEW5OUBvVQ>? MWnTRW5ITVJ?
NALM-6 NXfEZphWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXFTWM2OD1yLkC2NlIhdk1? MmHLV2FPT0WU
RPMI-6666 Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXTbnVKSzVyPUCuNFY2OiCwTR?= MYnTRW5ITVJ?
LC-2-ad NXPoW21tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi0bWxOUUN3ME2wMlA3PTNibl2= MkXRV2FPT0WU
ARH-77 NVjLbopPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnqcY1uUUN3ME2wMlA4OTFibl2= NHrNNY1USU6JRWK=
IST-MEL1 NVXFdGRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMEeyOkBvVQ>? MV\TRW5ITVJ?
SW1710 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMEe1NUBvVQ>? M2XYZXNCVkeHUh?=
DEL M4n2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW0TWM2OD1yLkC4PFchdk1? M2XWZXNCVkeHUh?=
AGS MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vzUmlEPTB;MD6wPVAzKG6P NVPnZVJNW0GQR1XS
NCI-H2122 M4HHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nrOGlEPTB;MD6wPVQ3KG6P MUPTRW5ITVJ?
HSC-4 NFvTO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTtTWM2OD1yLkGwNkBvVQ>? MnnzV2FPT0WU
AM-38 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;J[5RKSzVyPUCuNVIyKG6P NGrGO2ZUSU6JRWK=
769-P NEfSWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELOSZhKSzVyPUCuNVI{KG6P NGL5PZNUSU6JRWK=
RT-112 NGT6XmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzuTWM2OD1yLkGyO{BvVQ>? MULTRW5ITVJ?
MCF7 M3;4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3tTWM2OD1yLkGzOkBvVQ>? NX7BPYEyW0GQR1XS
IGROV-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMUS1JI5O NIPQVoVUSU6JRWK=
OCI-AML2 Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlryTWM2OD1yLkG0O{BvVQ>? MU\TRW5ITVJ?
NCI-H1299 M4jyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TUSGlEPTB;MD6xOVchdk1? M3;GcXNCVkeHUh?=
A431 NFvqZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMUizJI5O M13I[nNCVkeHUh?=
SW982 NInKbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;5TWM2OD1yLkKxN{BvVQ>? MXfTRW5ITVJ?
BB30-HNC MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnNdnhXUUN3ME2wMlI{OSCwTR?= Mn\3V2FPT0WU
ACN NWXkWXBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMkS0JI5O MXjTRW5ITVJ?
647-V MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\5[GlEPTB;MD6yOFghdk1? M17tSnNCVkeHUh?=
SK-PN-DW M3\jTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37GO2lEPTB;MD6yOlYhdk1? NUTDWGxXW0GQR1XS
LCLC-97TM1 M4nnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX4fWxLUUN3ME2wMlI3PyCwTR?= NWT5fYQ{W0GQR1XS
LB1047-RCC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\BTWM2OD1yLkK2PUBvVQ>? MlOxV2FPT0WU
A2780 NXrPTo13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XPVGlEPTB;MD6yO{BvVQ>? MoXrV2FPT0WU
C-33-A NVjtV|JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr1[pRDUUN3ME2wMlI4OyCwTR?= MYjTRW5ITVJ?
NCI-H2228 NEC4UHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS2TWM2OD1yLkOxOEBvVQ>? MofVV2FPT0WU
TE-5 NF;VV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv1e5pKSzVyPUCuN|E3KG6P MlvOV2FPT0WU
HC-1 NUXVPHJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jC[GlEPTB;MD6zNlchdk1? NIjM[oFUSU6JRWK=
SK-MES-1 NGW3emxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PsOWlEPTB;MD6zNlghdk1? Ml3wV2FPT0WU
NCI-H1355 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwM{ixJI5O NEX6c2FUSU6JRWK=
YKG-1 NG\0SoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwNEG5JI5O M3PC[3NCVkeHUh?=
RS4-11 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDHWJZtUUN3ME2wMlQ{OyCwTR?= M2fiPXNCVkeHUh?=
Daoy MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwNEW2JI5O MULTRW5ITVJ?
A3-KAW NYDNeG1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj6bZBEUUN3ME2wMlU2OSCwTR?= M2ewTXNCVkeHUh?=
SK-MEL-30 M4PIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjjeYlWUUN3ME2wMlU2PCCwTR?= MXHTRW5ITVJ?
U031 NYPzZ5hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrHTWM2OD1yLkW2OUBvVQ>? M3f3UXNCVkeHUh?=
SK-LMS-1 M1[wfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X6TWlEPTB;MD61O|ghdk1? NIi0fllUSU6JRWK=
ES6 NWPDd|B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq4WYZtUUN3ME2wMlU5PiCwTR?= MVPTRW5ITVJ?
EoL-1-cell NUf5bG1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHjTWM2OD1yLk[xOkBvVQ>? MkLnV2FPT0WU
NCI-H2009 NUjQcpc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr5TWM2OD1yLk[xPUBvVQ>? NXK4d5JlW0GQR1XS
A4-Fuk NH\NcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTWVWtwUUN3ME2wMlYzPiCwTR?= MomzV2FPT0WU
KYSE-270 NIHPT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L3b2lEPTB;MD62N|Qhdk1? NFrPPJVUSU6JRWK=
SK-LU-1 NXvPZ3ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;BPHQ2UUN3ME2wMlY2PSCwTR?= MYDTRW5ITVJ?
SW872 M3m4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz0TWM2OD1yLke2OUBvVQ>? MnvFV2FPT0WU
ES8 MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7LT5JnUUN3ME2wMlc5KG6P NWCwWohQW0GQR1XS
G-402 M1fmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj2TWM2OD1yLke4OEBvVQ>? NVmwcndRW0GQR1XS
ATN-1 NWfNNZVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILyTlVKSzVyPUCuPFA4KG6P NVn1eog5W0GQR1XS
DoTc2-4510 Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\wXYNKSzVyPUCuPVAyKG6P NYPPe4Y2W0GQR1XS
MES-SA Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\2TWM2OD1yLkmwOUBvVQ>? NFXGWllUSU6JRWK=
SF268 MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TuXGlEPTB;MD65Nlchdk1? NFfOeGVUSU6JRWK=
SF539 NWLQXIN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoqzTWM2OD1zLkCyJI5O NInkOZZUSU6JRWK=
NB69 NXz5clNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwMEWgcm0> NHHzfoNUSU6JRWK=
8505C M2fRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSwTWM2OD1zLkC2JI5O NGjNTFJUSU6JRWK=
CAL-12T NHK2dI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnETWM2OD1zLkC4JI5O M4O3eHNCVkeHUh?=
BHY M1\p[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi4OphJUUN3ME2xMlE1KG6P NFPDepVUSU6JRWK=
LB647-SCLC NITYSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[2VpRKSzVyPUGuNVghdk1? NIW5T3RUSU6JRWK=
CAL-62 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrXeWhKSzVyPUGuNlIhdk1? M4G2SXNCVkeHUh?=
MEG-01 NULN[YhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\oWWlEPTB;MT6yO{BvVQ>? MXHTRW5ITVJ?
MG-63 NXfWPXlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\BOlQzUUN3ME2xMlM{KG6P NGTmSpdUSU6JRWK=
SW620 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvmXWVlUUN3ME2xMlM2KG6P MnzLV2FPT0WU
A388 NF3QToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\jXGlEPTB;MT6zOkBvVQ>? MXrTRW5ITVJ?
BCPAP MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2SzO2lEPTB;MT60OUBvVQ>? NWLZW4RqW0GQR1XS
P30-OHK NXflXIZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfGeXdKSzVyPUGuOFYhdk1? M1W1SnNCVkeHUh?=
Ca9-22 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33EOGlEPTB;MT61OEBvVQ>? MV;TRW5ITVJ?
VMRC-RCZ Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjpToNKSzVyPUGuOVQhdk1? MYfTRW5ITVJ?
LOXIMVI NX:3T|lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3wTWM2OD1zLk[gcm0> NITrNFBUSU6JRWK=
L-540 MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\1N21KSzVyPUGuOkBvVQ>? NHexTG5USU6JRWK=
NTERA-S-cl-D1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj3bWhKSzVyPUGuOlQhdk1? MVvTRW5ITVJ?
MFH-ino MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml30TWM2OD1zLk[2JI5O MmDGV2FPT0WU
Calu-6 NFG2OnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf4TWM2OD1zLkezJI5O MnPsV2FPT0WU
HEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\ER5ZFUUN3ME2xMlc6KG6P MmfQV2FPT0WU
CAL-33 M3LiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PGfGlEPTB;MT64PUBvVQ>? M3HVUXNCVkeHUh?=
HSC-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWzTGdKSzVyPUGuPVEhdk1? MoP5V2FPT0WU
KU812 NEDEXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDzTJpKSzVyPUGuPVEhdk1? MYDTRW5ITVJ?
EB2 M1TCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO1c2dOUUN3ME2yMlAyKG6P MW\TRW5ITVJ?
SR NInOS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLSXm1KSzVyPUKuNVIhdk1? M1rtUXNCVkeHUh?=
NCI-H2087 M{jJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfJTWM2OD1{LkG0JI5O MVrTRW5ITVJ?
H4 MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\BTWM2OD1{LkG4JI5O Mne4V2FPT0WU
EW-1 NEnQdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f4bGlEPTB;Mj6yNkBvVQ>? MmPPV2FPT0WU
MC-IXC NVWzRoZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjp[GU4UUN3ME2yMlI3KG6P NX;2TpBMW0GQR1XS
NCI-H727 NX:1TpVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWxOZRKSzVyPUKuOVEhdk1? NVfGe5RmW0GQR1XS
MRK-nu-1 M3zI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFeydpRKSzVyPUKuOVchdk1? MmLYV2FPT0WU
COLO-668 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjVeW9sUUN3ME2yMlY3KG6P M2nNUXNCVkeHUh?=
CGTH-W-1 NXG5XnpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXOyU4VvUUN3ME2yMlczKG6P MmXKV2FPT0WU
CHP-212 NXnRNppYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkmyTWM2OD1{Lke1JI5O M33L[nNCVkeHUh?=
GI-1 NWrPOZE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJwN{[gcm0> MXHTRW5ITVJ?
HCC1806 NY[ye2NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJwOUGgcm0> Ml;xV2FPT0WU
HLE NUj5SYZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTNibl2= M3XvN3NCVkeHUh?=
HSC-2 NGW4blhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjwTWM2OD1|LkCzJI5O NHfSbVZUSU6JRWK=
DMS-273 M1\ycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNwMEegcm0> NHvNNG1USU6JRWK=
DU-4475 NYLZdZNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHyfVZ[UUN3ME2zMlE1KG6P NH\XZ2JUSU6JRWK=
LXF-289 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jiUGlEPTB;Mz6zNUBvVQ>? NUn4S41vW0GQR1XS
PANC-03-27 M3PZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v0fWlEPTB;Mz61NUBvVQ>? MWDTRW5ITVJ?
GAMG NYj0enhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPGTWM2OD1|Lke0JI5O M4XUbXNCVkeHUh?=
NCI-H522 NFrRTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnyVGMxUUN3ME20MlM1KG6P MUPTRW5ITVJ?
SW626 M37OUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jlfGlEPTB;ND60OkBvVQ>? M1XyVXNCVkeHUh?=
HT-144 NH7ZcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRwOUKgcm0> NInFe5pUSU6JRWK=
MEL-HO NYj1cJp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH0SJdKSzVyPUWuNVYhdk1? NV;H[pB1W0GQR1XS
BE-13 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWzZ2tKSzVyPUWuNlEhdk1? MXzTRW5ITVJ?
VA-ES-BJ MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXKz[WxwUUN3ME21MlI3KG6P NF[wfXlUSU6JRWK=
NCI-H441 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LXXmlEPTB;NT62JI5O NVziUWhrW0GQR1XS
KP-4 NX;1WYk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTVwNkGgcm0> NYXMe4lOW0GQR1XS
LoVo NH7ENoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTVwN{Ggcm0> NI\pbm1USU6JRWK=
HT-1080 M4f0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTVwOEOgcm0> MYLTRW5ITVJ?
GB-1 NVfIbZhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS1Z2tSUUN3ME21Mlg1KG6P MofmV2FPT0WU
IA-LM NHnTc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX6TWM2OD13LkmxJI5O NFfm[nVUSU6JRWK=
8-MG-BA MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof5TWM2OD13LkmzJI5O M37QbnNCVkeHUh?=
SK-HEP-1 M2jUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWriTpBkUUN3ME22MlE1KG6P MVfTRW5ITVJ?
697 NY\TcG1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnQTWM2OD14LkK1JI5O NEH0SopUSU6JRWK=
KYSE-450 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTZwM{Kgcm0> NW\ST4hXW0GQR1XS
HCC2998 MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3qwXmlEPTB;Nj6zOEBvVQ>? M4HvVHNCVkeHUh?=
HD-MY-Z NX34VpR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\yRmt[UUN3ME22MlY5KG6P NULQb|ZjW0GQR1XS
OS-RC-2 NHfvfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\WTWM2OD14Lk[4JI5O M4n6WHNCVkeHUh?=
SF126 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkixTWM2OD15LkC1JI5O M4rSOXNCVkeHUh?=
Ca-Ski NVTKbnlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknnTWM2OD15LkC5JI5O MULTRW5ITVJ?
NCI-H358 NHLMfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLQTWM2OD15LkG2JI5O M3rJ[3NCVkeHUh?=
J82 NUDYWJNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnnT4xnUUN3ME23MlQyKG6P MYrTRW5ITVJ?
NCI-H2342 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTdwNkOgcm0> M3y0WXNCVkeHUh?=
OVCAR-8 M1L5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPTTWM2OD15Lkmgcm0> MWTTRW5ITVJ?
TE-8 MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzlWoZKSzVyPUigcm0> NG\mU3JUSU6JRWK=
ETK-1 NUj6[5kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRThwMEigcm0> NHq5VmlUSU6JRWK=
HAL-01 NXjMXY5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\BTWM2OD16LkKgcm0> M1HTT3NCVkeHUh?=
KYSE-150 NGrIU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnNZZVuUUN3ME24MlQ4KG6P M4ewSnNCVkeHUh?=
NCI-H810 M17UUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRThwNU[gcm0> NXG1Z2d1W0GQR1XS
ONS-76 NXTGTnU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XtdWlEPTB;OD62PEBvVQ>? NGHyfmtUSU6JRWK=
NMC-G1 M37WfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D5cWlEPTB;OD63OkBvVQ>? MVXTRW5ITVJ?
C3A M4HtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRThwOESgcm0> M3:wNnNCVkeHUh?=
PA-1 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\SO2lEPTB;OD65PUBvVQ>? MUnTRW5ITVJ?
SH-4 NGT1doVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TOfGlEPTB;OT6wNkBvVQ>? MY\TRW5ITVJ?
EFO-27 MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPJc2RGUUN3ME25MlA2KG6P NV;EOnN[W0GQR1XS
CAPAN-1 M3f4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDtUlZHUUN3ME25MlI{KG6P MXPTRW5ITVJ?
DU-145 NF\mbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7UcZlKSzVyPUmuNlkhdk1? MofWV2FPT0WU
A101D NITmeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTlwM{egcm0> NWqxN21NW0GQR1XS
ST486 NIPt[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXL3b5Z{UUN3ME25MlQyKG6P NEjK[mZUSU6JRWK=
NCI-H1437 NFvNflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjrTWM2OD17LkSyJI5O NIe4ZWhUSU6JRWK=
HGC-27 NXTuOnVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr0TWM2OD17Lk[gcm0> NH3uV41USU6JRWK=
8305C NHXCdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vzSWlEPTB;OT62OEBvVQ>? NGDkeJRUSU6JRWK=
OCUB-M NU[0bI5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NECzW|RKSzVyPUGwMlA{KG6P MlHLV2FPT0WU
COLO-679 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfRTWM2OD1zMD6wO{BvVQ>? M2m1NHNCVkeHUh?=
Detroit562 NWPYWW1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTMVWhPUUN3ME2xNE41OiCwTR?= NIrxUWFUSU6JRWK=
A204 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrrVoVTUUN3ME2xNU4yPiCwTR?= MmfqV2FPT0WU
NCI-H1734 M4OySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFzLkK5JI5O MlK3V2FPT0WU
MC-CAR NVTuXWU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;XeGlEPTB;MUGuOVghdk1? NWOwTG1wW0GQR1XS
NCI-H2170 M1qzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HNR2lEPTB;MUGuPVchdk1? NYPxNoRjW0GQR1XS
NCI-SNU-5 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rrUmlEPTB;MUKuNVMhdk1? M2T4cXNCVkeHUh?=
HCE-T NVTufmJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v3b2lEPTB;MUKuOFIhdk1? NHOwZlRUSU6JRWK=
KYSE-180 M1G0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfoOlVoUUN3ME2xNk45OSCwTR?= NWDOU2lvW0GQR1XS
C8166 NUjRSIY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF|LkC4JI5O NXr3PYZGW0GQR1XS
NCI-H460 NYnqTXNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHIOHJbUUN3ME2xN{42PCCwTR?= M1nGeHNCVkeHUh?=
SNU-449 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H2N2lEPTB;MUOuO|chdk1? M123dXNCVkeHUh?=
MDA-MB-468 NFL1TXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnUZY1KSzVyPUG0MlEzKG6P MV;TRW5ITVJ?
COR-L23 NFz6N29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\ITWM2OD1zND6xN{BvVQ>? MnnpV2FPT0WU
CTV-1 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HOT2lEPTB;MUSuNVQhdk1? MXHTRW5ITVJ?
BL-41 M1vXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1flcGlEPTB;MUSuN|chdk1? NWDMboV5W0GQR1XS
IGR-1 NHzNPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDlUpdDUUN3ME2xOE41OiCwTR?= MVHTRW5ITVJ?
TK10 NH\vOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi4e5lKSzVyPUG0MlQ6KG6P Mkj4V2FPT0WU
REH NHyyfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3acnFKSzVyPUG0MlUyKG6P MnvwV2FPT0WU
LU-139 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF2LkW5JI5O MnHMV2FPT0WU
KP-N-YS NX3OZpZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF2Lkm3JI5O NVLxPG52W0GQR1XS
PANC-10-05 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XWfmlEPTB;MUWuN|ghdk1? NHy4PJFUSU6JRWK=
HL-60 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF3Lk[5JI5O NHzL[nRUSU6JRWK=
T84 NIPDfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLLZ2l1UUN3ME2xOU46PiCwTR?= NHG5dWRUSU6JRWK=
RPMI-8226 NEKzTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF4LkCyJI5O NX\VdYtVW0GQR1XS
UM-UC-3 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrtXY9CUUN3ME2xOk4yPiCwTR?= NUXIZWZ7W0GQR1XS
TE-10 M4DKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoSzTWM2OD1zNj6yNUBvVQ>? MV;TRW5ITVJ?
CAL-148 NIT5ZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXvNpN4UUN3ME2xO{4zOyCwTR?= NF22UlhUSU6JRWK=
BV-173 M4HKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHMb5VCUUN3ME2xO{4zPyCwTR?= MormV2FPT0WU
Calu-3 MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XNNWlEPTB;MUeuNlkhdk1? NV7PVJA3W0GQR1XS
RPMI-2650 NIrrUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzRTWM2OD1zNz61PUBvVQ>? NUfo[lZJW0GQR1XS
MKN45 NX7ldGl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF5LkezJI5O MXnTRW5ITVJ?
NUGC-3 NX;yfZhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF6LkO0JI5O M1nKfnNCVkeHUh?=
NCI-H520 NXnlW4poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrITWM2OD1zOD63O{BvVQ>? NH3zUHJUSU6JRWK=
CCRF-CEM NY\xe5d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLv[W1KSzVyPUG4Mlg2KG6P MoHSV2FPT0WU
NCI-H2405 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTLTWM2OD1zOT6xJI5O M3rqVHNCVkeHUh?=
ES7 NHXkcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rPOmlEPTB;MUmuO|Yhdk1? MmnWV2FPT0WU
BPH-1 NF;FSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvoPGVKSzVyPUKwMlI5KG6P Mn7aV2FPT0WU
SAS MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJyLkWgcm0> MUPTRW5ITVJ?
HuCCT1 MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDkbGFbUUN3ME2yNE42QCCwTR?= MY\TRW5ITVJ?
LOUCY MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;ERYpKSzVyPUKwMlY3KG6P NHXKfXNUSU6JRWK=
NCI-H292 MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HkWmlEPTB;MkCuO|khdk1? M17TbnNCVkeHUh?=
G-361 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC0TWM2OD1{MT6wO{BvVQ>? M2DNdXNCVkeHUh?=
M059J Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXLS29KSzVyPUKxMlA5KG6P NWnONIFCW0GQR1XS
NCI-H1651 M4[zXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD1[G53UUN3ME2yNU4yOSCwTR?= MkT4V2FPT0WU
KALS-1 M{TYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHBTWM2OD1{MT6zPUBvVQ>? MV7TRW5ITVJ?
DJM-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XaV2lEPTB;MkGuOVkhdk1? NYrrWIhiW0GQR1XS
AU565 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULWU45OUUN3ME2yNU45OyCwTR?= M13ZZXNCVkeHUh?=
HCC38 NFHqW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHPNIcxUUN3ME2yNU46PSCwTR?= NWPldJRwW0GQR1XS
U251 NF\BbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDm[GtKSzVyPUKyMlI4KG6P NWfvfphVW0GQR1XS
ABC-1 NIL6W41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi0XmRKSzVyPUKyMlY2KG6P MVHTRW5ITVJ?
SK-NEP-1 M{LsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\xT5RKSzVyPUKyMlk{KG6P Mm\5V2FPT0WU
CESS MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO0bI9WUUN3ME2yN{4yQSCwTR?= MnTNV2FPT0WU
MIA-PaCa-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:xXWlEPTB;MkOuN|Yhdk1? Ml[yV2FPT0WU
SUP-T1 NWHzS5A{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHETWM2OD1{Mz60O{BvVQ>? MV\TRW5ITVJ?
L-428 NV\rWZlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\XZWlEPTB;MkOuOlIhdk1? MVLTRW5ITVJ?
SW954 NITZc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rNNmlEPTB;MkOuOlghdk1? Ml:3V2FPT0WU
HO-1-N-1 NHvk[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjt[mZKSzVyPUKzMlc4KG6P NGjJdHlUSU6JRWK=
CHP-126 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTndmNKSzVyPUK0MlE1KG6P MnXKV2FPT0WU
HMV-II MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHrRZl4UUN3ME2yOE4{PCCwTR?= NFG4d4FUSU6JRWK=
NB10 NU\TOWoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rFNGlEPTB;MkSuN|chdk1? NF7oc4pUSU6JRWK=
A172 M4DRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLV[Yg6UUN3ME2yOE44OSCwTR?= MUHTRW5ITVJ?
MONO-MAC-6 NGDDZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJ2Lki0JI5O M3;3cXNCVkeHUh?=
NCI-H1650 NXXUNpRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DQN2lEPTB;MkWuOEBvVQ>? M331fXNCVkeHUh?=
NH-12 NV3LR4RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjtVHc1UUN3ME2yOU42KG6P M4\jcnNCVkeHUh?=
ML-2 NGLrR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPh[WxrUUN3ME2yOU44PCCwTR?= NFTET5hUSU6JRWK=
MZ2-MEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7PTWM2OD1{Nj6yNkBvVQ>? MYjTRW5ITVJ?
COLO-684 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLGe3lKSzVyPUK2MlQyKG6P M2PpZ3NCVkeHUh?=
HuP-T4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf6RXlKSzVyPUK3MlMhdk1? MXLTRW5ITVJ?
SW837 NF;Yd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ5Lk[yJI5O NFXEUJdUSU6JRWK=
MDA-MB-231 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3wTWM2OD1{Nz63PEBvVQ>? NXGzW2RpW0GQR1XS
KYSE-140 M4\Ke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fsSWlEPTB;MkeuPVEhdk1? NU\YNWlEW0GQR1XS
NOMO-1 NX;JO4pzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf2dI5KSzVyPUK4MlY5KG6P NVnFW4w4W0GQR1XS
GP5d M4GzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi0Nlk6UUN3ME2yPE44OiCwTR?= MYLTRW5ITVJ?
COR-L105 M4rGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;XZWlEPTB;MkmuOFIhdk1? MnX6V2FPT0WU
LS-411N NUfwNHExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfwTWM2OD1{OT64PEBvVQ>? MonYV2FPT0WU
NY NVX2cFZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzHTWM2OD1|MD6xPEBvVQ>? NHLLbZdUSU6JRWK=
NCI-H2030 MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInKcXJKSzVyPUOwMlQ2KG6P M3;GUXNCVkeHUh?=
CCF-STTG1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTNzLkSyJI5O M4X0eXNCVkeHUh?=
NCI-H1703 NYHYdI5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjENmgzUUN3ME2zNU44QCCwTR?= NEHCfGhUSU6JRWK=
TUR M1rqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVizUohtUUN3ME2zNk4xOyCwTR?= NV7FR|dIW0GQR1XS
NOS-1 NX74VVJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi1TWM2OD1|Mj60OEBvVQ>? M3zYVXNCVkeHUh?=
A2058 NXjQbG1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTN{LkizJI5O M3nSbXNCVkeHUh?=
LCLC-103H NFXlUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTN|LkK1JI5O M2W4[3NCVkeHUh?=
NCI-H510A M3;UVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLTTWM2OD1|Mz6yO{BvVQ>? MnL0V2FPT0WU
BC-1 M4jTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPHU3BoUUN3ME2zN{44PyCwTR?= M1PGZ3NCVkeHUh?=
SK-CO-1 NUPGWI1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkG0TWM2OD1|ND6wNUBvVQ>? MnixV2FPT0WU
A673 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;YO2ZiUUN3ME2zOE4yPyCwTR?= NWfXdIFEW0GQR1XS
VM-CUB-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTRTWM2OD1|ND62PUBvVQ>? Mlv5V2FPT0WU
HH NGKweZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnvTWM2OD1|NT6wOkBvVQ>? M2fjZ3NCVkeHUh?=
CAL-27 MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\JcFRKSzVyPUO1MlE3KG6P NV\MWpg4W0GQR1XS
NEC8 NUHHOpR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7QVlZKSzVyPUO1MlM4KG6P MlL4V2FPT0WU
BxPC-3 NE\KT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzP[3F4UUN3ME2zOk46OSCwTR?= MV;TRW5ITVJ?
SNB75 M1rKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTN5LkK0JI5O M2nuV3NCVkeHUh?=
NB13 NUn6TY81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LhNGlEPTB;M{iuNlMhdk1? NYnTPFF2W0GQR1XS
SK-OV-3 M3XFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzETWM2OD1|OD63OEBvVQ>? MXHTRW5ITVJ?
ME-180 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;WTWM2OD1|OD64JI5O M3XiWnNCVkeHUh?=
JiyoyeP-2003 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz3TWhRUUN3ME2zPU4{QCCwTR?= M4DLbXNCVkeHUh?=
LU-134-A NIjmTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTRyLkCyJI5O M4PpcXNCVkeHUh?=
LS-123 MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uwWWlEPTB;NECuNlghdk1? NEHRZVhUSU6JRWK=
COLO-800 M2jwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHPTWM2OD12MD61OkBvVQ>? NF:1e4lUSU6JRWK=
LB831-BLC NVjvPJRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi2flVKSzVyPUSxMlg2KG6P MlHrV2FPT0WU
NCI-H747 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7nTWM2OD12Mj6yPEBvVQ>? M3n1VHNCVkeHUh?=
MZ7-mel MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTR{Lk[2JI5O MnLDV2FPT0WU
GT3TKB NVG0ToY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTR{LkeyJI5O NUP3[3hCW0GQR1XS
MOLT-16 NYTxPY1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTR|LkC1JI5O MmPzV2FPT0WU
23132-87 NYrVNlBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\4TWM2OD12Mz6wOUBvVQ>? Mk\kV2FPT0WU
PF-382 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzoOGxKSzVyPUS0MlIzKG6P NIqxe|dUSU6JRWK=
ES3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDYZlZOUUN3ME20OE43KG6P MkG1V2FPT0WU
SW756 M1fXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTNNosxUUN3ME20OU4yPCCwTR?= NI\uR|VUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p70S6K1 / p-S6 / HIF-1α ; 

PubMed: 27765914     


Cells were treated with different doses of gemcitabine (0, 1.5 and 2.5 μM), the expression levels of p70S6K1, p-S6 and HIF-1α were determined by Western blotting. GAPDH is used as an internal control.

PARP / Cleaved PARP / Cleaved caspase-3 / phopho-p38 / p38 / p-JNK / JNK / p-c-Jun; 

PubMed: 24409315     


AsPC-1, BxPC-3, and COLO-357 cells were incubated for the indicated times with 100 ng/ml, 10 ng/ml, and 5 ng/ml gemcitabine, respectively, and analyzed by immunoblotting. 

27765914 24409315
Immunofluorescence
Bim1; 

PubMed: 27177084     


Gemcitabine enhanced nuclear accumulation of Bmi1 by immunofluorescence staining. The graphs shown are representative results of three independently repeated experiments. Scale bar, 50 μm.

27177084
Growth inhibition assay
Cell viability; 

PubMed: 27765914     


A and B. Pancreatic adenocarcinoma cells Bxpc-3 (A) and Panc-1 (B) were treated with gemcitabine (GEM) for 48 h at different doses. The cell viability was analyzed by CCK-8 assay, and normalized to cells without gemcitabine treatment. 

27765914
In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water (warmed)
For best results, use promptly after mixing.
52mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327
Smiles C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04383119 Not yet recruiting Drug: Trabectedin|Drug: Gemcitabine Leiomyosarcoma of Ovary|Soft Tissue Sarcoma Italian Sarcoma Group|PharmaMar September 1 2020 Phase 2
NCT04521686 Recruiting Drug: LY3410738 Cholangiocarcinoma|Chondrosarcoma|Glioma|Any Solid Tumor Loxo Oncology Inc.|Eli Lilly and Company August 2020 Phase 1
NCT04338763 Not yet recruiting Drug: RP72|Drug: Gemcitabine Pancreatic Cancer|Pancreatic Cancer Non-resectable|Pancreatic Cancer Metastatic Rise Biopharmaceuticals Inc.|Amarex Clinical Research April 30 2020 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID